Company news
Paradigm Biopharmaceuticals Ltd. news in 2019
Paradigm Biopharmaceuticals Ltd.'s news releases, calls and decks from 2019, newest first.
Cleansing Notice and Appendix 3B
December 18, 2019
Paradigm End of Calendar Year Update
December 11, 2019
Paradigm AGM Presentation
November 7, 2019
Paradigm provides regulatory filing update
October 24, 2019
Osteoarthritis pain reduced by Paradigms Zilosul (PPS)
September 29, 2019
PAR Expanded Access IND Cleared by US FDA
September 10, 2019
Appendix 4E and 2019 Annual Report
August 30, 2019
PARs drug reduces cartilage degradation in subjects with OA
August 28, 2019
Paradigm files first IND with US FDA
August 6, 2019
Appendix 4C - quarterly
July 31, 2019
Paradigm EOFY Update
June 28, 2019
PAR reports successful Ross River phase 2 clinical trial
June 3, 2019
PAR reports consistent pain reduction in knee OA of patients
May 27, 2019
PAR corrects AFR article
May 21, 2019
Successful Completion of Retail Entitlement Offer
May 8, 2019
Paradigm Corporate Update - May 2019
May 7, 2019
Quarterly Report and Appendix 4C - quarterly
April 30, 2019
Completion of Institutional Entitlement Offer
April 23, 2019
PAR Accelerated Non-Renounceable Rights Issue Offer Booklet
April 16, 2019
Paradigm Confirms Capital Raise Commitments
April 16, 2019
Paradigm updated corporate presentation
April 14, 2019
Paradigm launches a$77.9M capital raise
April 14, 2019
Paradigms secondary endpoints successfully met
April 14, 2019
Paradigm (PAR) Updated Investor Presentation
March 12, 2019
S&P DJI Announces March 2019 Quarterly Rebalance
March 7, 2019
Paradigms orphan Phase 2/3 clinical program progresses
February 13, 2019
Decks in 2019
- Shareholder Meeting (November 2019)
Shareholder meeting · 25 slides · Nov 7, 2019
- Investor Presentation (April 2019)
Investor deck · 40 slides · Apr 15, 2019
- Investor Presentation (March 2019)
Investor deck · 38 slides · Mar 13, 2019